acquired
Stage
2009
Founded
3
Investors
About
Orphazyme was a biopharmaceutical company focused on developing therapies for rare neurodegenerative diseases, particularly lysosomal storage disorders. Its primary drug candidate was arimoclomol, a heat shock protein response modulator.
Explore Orphazyme's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.